← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Global Vaccines, Inc.
Research Triangle Park, NC
$11,567,552
Total funding
7
Grants
Funding over time
peak $2.5M · FY2006–14$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$11,567,552 · 7
By mechanism
U01$8,765,072 · 2
R01$2,051,801 · 1
R21$414,971 · 1
F32$335,708 · 3
Investigators at Global Vaccines, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
A Tetravalent Dengue Vaccine Based on Alphavirus Replicons$1,379,658
U01 · FY2011 · AI
A Novel Systemic and Mucosal Adjuvant for Biodefense$1,244,356
U01 · FY2006 · AI
A Novel Systemic and Mucosal Adjuvant for Biodefense$1,175,233
U01 · FY2009 · AI
A Novel Systemic and Mucosal Adjuvant for Biodefense$1,166,198
U01 · FY2007 · AI
A Novel Systemic and Mucosal Adjuvant for Biodefense$1,141,009
U01 · FY2008 · AI
A Tetravalent Dengue Vaccine Based on Alphavirus Replicons$1,070,488
U01 · FY2012 · AI
A Novel Systemic and Mucosal Adjuvant for Biodefense$1,069,641
U01 · FY2009 · AI
Role of innate immune responses in the activity of an Alphavirus based adjuvant.$566,898
R01 · FY2014 · AI
Role of innate immune responses in the activity of an Alphavirus based adjuvant.$566,898
R01 · FY2012 · AI
Role of innate immune responses in the activity of an Alphavirus based adjuvant.$532,884
R01 · FY2013 · AI
A Novel Systemic and Mucosal Adjuvant for Biodefense$518,489
U01 · FY2010 · AI
Role of innate immune responses in the activity of an Alphavirus based adjuvant.$385,121
R01 · FY2011 · AI
A Propagating Chimeric Particle as a Safe Alternative to Live-Attenuated Virus$226,359
R21 · FY2010 · AI
A Propagating Chimeric Particle as a Safe Alternative to Live-Attenuated Virus$188,612
R21 · FY2009 · AI
Effect of a viral replicon adjuvant on dendritic cell activity$50,474
F32 · FY2010 · AI
Propagation Enhancement of Chimeric Lentiviral Vaccines$50,428
F32 · FY2008 · AI
Propagation Enhancement of Chimeric Lentiviral Vaccines$48,796
F32 · FY2007 · AI
Role of innate immunity in responding to an alphavirus-based adjuvant$47,606
F32 · FY2010 · AI
Effect of a viral replicon adjuvant on dendritic cell activity$47,210
F32 · FY2009 · AI
Propagation Enhancement of Chimeric Lentiviral Vaccines$45,976
F32 · FY2006 · AI